NCT04899908: Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must meet at least one of the following: 1 HER2+ breast cancer, 2 Metastases that are greater than or equal to 2cm, 3 Locally recurrent metastases after prior stereotactic radiation or whole brain radiation
Exclusions: Patients with widespread, definitive leptomeningeal disease; Patients requiring radiation to greater than 10 targets (if naïve to whole brain radiation) or greater than 20 targets (if whole brain radiation has been given previously)

Comments are closed.

Up ↑